MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
EQS-News: MorphoSys AG / Key word(s): Conference Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be highlighted during an oral presentation on Friday, May 31, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The congress is being held in Chicago, Illinois, from May 31 to June 4, 2024. Additionally, new data from the Phase 2 study of tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, in patients with advanced solid tumors or hematologic malignancies will be showcased in a poster presentation at ASCO 2024. ASCO 2024 Presentation Details
The full text of each abstract will be available on May 23 at 4:00 p.m. CDT. Please refer to the ASCO 2024 online program for full session details and data presentation listings. About MorphoSys About Pelabresib The development of pelabresib was funded in part by The Leukemia and Lymphoma Society. About MANIFEST-2 Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others. Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor. About Myelofibrosis About Tulmimetostat For more information, please contact:
24.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
EQS-News:MorphoSys AG /关键词:会议 媒体发布 Planegg/德国慕尼黑,2024 年 4 月 24 日 MorphoSys 将在 2024 年 ASCO 年会上以口头陈述的形式公布有关骨髓纤维化中 Pelabresib 的 3 期 MANIFEST-2 新数据 2024 年 ASCO 的其他海报展示将包括塔尔米美托司他二期研究的新发现 MorphoSys AG(FSE:MOR;纳斯达克股票代码:MOR)今天宣布,将在5月31日星期五的2024年美国临床肿瘤学会(ASCO)年度会议上发表口头演讲,重点介绍研究性BET抑制剂pelabresib与JAK抑制剂鲁索利替尼联合对JAK抑制剂纯真的骨髓纤维化患者的3期 MANIFEST-2 试验的新疗效和安全性数据会议。该大会将于2024年5月31日至6月4日在伊利诺伊州芝加哥举行。 此外,针对晚期实体瘤或血液系统恶性肿瘤患者的tulmimetostat(一种正在研究的下一代EZH2和EZH1双重抑制剂)的2期研究的新数据将在ASCO 2024的海报展示中展示。 ASCO 2024 演示详情
每份摘要的全文将于中部夏令时间5月23日下午 4:00 公布。请参阅 ASCO 2024 在线项目 获取完整的会话详细信息和数据演示清单。 关于 MorphoS 关于 Pelabresib pelabresib 的开发部分由白血病和淋巴瘤协会资助。 关于 MANIFEST-2 其他次要终点包括无进展存活率、总存活率、脾脏和总症状评分反应的持续时间、血红蛋白反应率和骨髓纤维化的改善等。 MorphoSys 旗下的 Constellation Pharmaceuticals, Inc. 是 MANIFEST-2 的试验赞助商。 关于骨髓纤维化 关于 Tulmimetostat 欲了解更多信息,请联系:
欧洲中部时间/欧洲中部夏令时间2024年4月24日发布企业新闻,由EQS集团股份公司旗下的EQS新闻播出。 |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1887399 |
语言: | 英语 |
公司: | Morphosys |
塞梅尔韦斯大街 7 | |
82152 Planegg | |
德国 | |
电话: | +49 (0) 89 899 27-0 |
传真: | +49 (0) 89 899 27-222 |
电子邮件: | investors@morphosys.com |
互联网: | www.morphosys.com |
ISIN: | DE0006632003 |
赢了: | 663200 |
指数: | MDAX、TecDAX |
已列出: | 法兰克福的受监管市场(Prime Standard);柏林、杜塞尔多夫、汉堡、汉诺威、慕尼黑、斯图加特、Tradegate交易所的受监管的非官方市场;纳斯达克 |
EQS 新闻 ID: | 1887399 |
End of News | EQS News Service |
新闻结尾 | EQS 新闻服务 |